Completed NA INTERVENTIONAL 2-arm NCT00651755

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma

Sponsor: M.D. Anderson Cancer Center

Conditions Lymphoma

Interventions Aprepitant Cyclophosphamide Doxorubicin Ondansetron Prednisone Rituximab Vincristine

Updated 6 times since 2017 Last updated: Jun 28, 2013 Started: Mar 31, 2008 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00651755, this NA trial focuses on Lymphoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jun 2022 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States